Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial

NCT05269485 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT05269485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2022
Completion date
January 30, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, radiotherapy side effect